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A wide spectrum of skin toxicities has been described in patients receiving epidermal growth factor receptor (EGFR), inhibitors,
including papulopustular rash, xerosis and fissures, pruritus, mucositis, paronychia, and hair changes.Trichomegaly of the
eyelashes is a rare adverse effect of EGFR inhibitor therapy and is characterized by a paradoxical overgrowth of eyelashes. We
present 3 cases of trichomegaly occurred during EGFR inhibitor therapy.
THE OVEREXPRESSION of the epidermal growth factor re-ceptor (EGFR) is strongly associated with cancer development.
It is known that EGFR can be inhibited by monoclonal antibodies
such as cetuximab and panitumumab or by small-molecule tyrosine
kinase inhibitors such as erlotinib and geﬁtinib.1
The higher speciﬁc pharmacological target of these drugs can
lower hematologic toxicity, but the risk of dermatological reactions
is quite higher related to these drugs.2 The EGFR, in fact, is ex-
pressed in basal and suprabasal layers of the epidermis, in seba-
ceous glands, and in the outer root sheath of the hair follicles.3
A wide spectrum of skin toxicities has been described in
patients receiving EGFR inhibitors, including papulopustular
rash, xerosis and ﬁssures, pruritus, mucositis, paronychia, and
hair changes. All these adverse effects can have signiﬁcant physical
and emotional discomfort.4
Hypertrichosis refers to excessive hair growth in normally
hairy, nonYandrogen-dependent regions. Trichomegaly of the eye-
lashes is a rare adverse effect of EGFR inhibitor therapy and is
characterized by a paradoxical overgrowth of eyelashes. It usually
occurs in 2 to 5 months after the start of treatment and may resolve
in several weeks or months after discontinuation of treatment.5
We present 3 cases of trichomegaly that occurred during EGFR
inhibitor therapy.
CASE REPORT
All 3 patients were females and referred to our outpatient de-
partment from February through September 2011.
The ﬁrst patient, aged 45 years, had a metastatic gastric cancer
and was put on therapy with panitumumab + FOLFOX protocol
(5-FU + folinic acid + oxaliplatinum) for 3 months. Six weeks after
starting panitumumab, she developed an abnormal growth of her
eyelashes (Fig. 1).
The second patient, aged 54 years, had a metastatic gastric can-
cer too. She had been on therapy with panitumumab for 4 months
in the last year, and she had suspended therapy 6 months before
our observation. Three months after administration of panitumu-
mab, she noticed the development of long, curly eyelashes. This
clinical sign was maintained during the whole duration of the
therapy and persisted for 6 months after its discontinuation (Fig. 2).
The third patient had metastatic lung cancer and has been
under treatment with erlotinib for 3 months. She had been pre-
viously treated with 4 cycles of cisplatinum + vinorelbine and
2 cycles of pemetrexed. Eight weeks after starting erlotinib, she
developed trichomegaly (Fig. 3).
All the 3 patients had long and curly eyelashes, without asso-
ciated symptoms such as pain or itching. They showed also other
signs of EGFR inhibitor skin toxicity.
The ﬁrst patient showed a papulopustular rash (G2 grad-
ing according to the Common Toxicity Criteria version 4.03)
involving the trunk and face; furthermore, she had hypertrichosis
of the face.
Figure 1A. Trichomegaly during treatment with panitunumab.
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Even if the second patient had already interrupted panitu-
mumab when she came to our observation, she still showed par-
onychia and dry skin as delayed adverse effects of this therapy.
Moreover, she referred that she had had a papulopustular rash
during the treatment with panitumumab; this rash disappeared
after the suspension of the therapy.
The third patient showed a papulopustular rash that started
after the ﬁrst 2 weeks of treatment with erlotinib. Lesions involved
less than 50% of the body surface and were associated with mod-
erate pruritus (G2 grading according to the Common Toxicity
Criteria version 4.03). In the last month, the patient had also noted
changes in the quality of her hair, which at our observation were
curly and brittle.
The pathogenesis of trichomegaly related to the assumption of
EGFR inhibitors is not completely understood. Epidermal growth
factor receptor is expressed in the keratinocytes of the outer sheath
of the hair follicle, and it acts such as an on/off switch at the be-
ginning and at the end of the anagen phase. The inhibition of the
EGFR signaling disrupts the progression of the anagen to the telo-
gen phase, leading to an aberrant anagen phase and subsequently
to abnormal hair growth. This can stimulate the formation of a dis-
organized hair follicle.6
Anyway, it is not well understood how these drugs can be re-
sponsible for frailer scalp hair and stronger and longer lashes.
Although this kind of disorder is rarely related to pain, pruritus,
or any kind of discomfort, it can represent an important cause of
aesthetic damage, especially for female patients. Periodical trim-
ming is an appropriate therapeutic modality. This adverse effect
tends to persist for the duration of the treatment with EGFR inhi-
bitors, and it could last for a long period after drug discontinua-
tion, as in our second patient.
Sometimes, the elongation of eyelashes can be complicated
by trichiasis and secondary corneal ulceration. For this reason,
patients affected by trichomegaly should have ophthalmologic
consultation.
With the increasing use of this new class of drugs, dermatolo-
gists and oncologists should be aware of this effect. An early iden-
tiﬁcation of trichomegaly can protect patients from ocular damages
and can improve their quality of life.
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Figure 2. Trichomegaly during treatment with erlotinib.
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